Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -282.13% is in line with its 3-year average of -286.62%, around the middle of its 3-year range (-661.53%–-78.27%).
As of the fiscal period ended Tuesday, June 30, 2026. 38.16% above its 12-month average of -456.23%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -282.13%.
RETURN ON EQUITY (ROE)
-282.13%
RETURN ON EQUITY (ROE) AVG TTM
-456.23%
RETURN ON EQUITY (ROE) AVG 3Y
-286.51%
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+38.16%
CURRENT VS 3Y AVG
+1.53%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-38.42%
median of 446 covered companies
CURRENT VS SECTOR MEDIAN
-634.32%
vs the sector median at left
Cadrenal Therapeutics, Inc. Common Stock
Market Cap
$3.37M
Return on Equity (ROE)
-282.13%
TTM Avg
-456.23%
3Y Avg
-286.51%
5Y Avg
N/A
Market Cap
$3.34M
Return on Equity (ROE)
-133.43%
TTM Avg
-203.84%
3Y Avg
-174.81%
5Y Avg
-140.61%
Market Cap
$3.47M
Return on Equity (ROE)
-141.90%
TTM Avg
-194.17%
3Y Avg
-143.89%
5Y Avg
-113.05%
Market Cap
$3.39M
Return on Equity (ROE)
N/A
TTM Avg
5741.84%
3Y Avg
2797.55%
5Y Avg
1847.94%
Market Cap
$3.04M
Return on Equity (ROE)
-365.43%
TTM Avg
-2048.73%
3Y Avg
-1082.52%
5Y Avg
-614.77%
Market Cap
$3.07M
Return on Equity (ROE)
N/A
TTM Avg
-236.13%
3Y Avg
-104.67%
5Y Avg
-48.54%
Market Cap
$3.98M
Return on Equity (ROE)
-437.15%
TTM Avg
-328.44%
3Y Avg
-188.67%
5Y Avg
-533.64%
Market Cap
$2.64M
Return on Equity (ROE)
-657.69%
TTM Avg
-358.53%
3Y Avg
-220.37%
5Y Avg
-149.08%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cadrenal Therapeutics, Inc. Common Stock (CVKD) | $3.37M | -282.13% | -456.23% | -286.51% | N/A |
| Aethlon Medical, Inc. (AEMD)vs › | $3.34M | -133.43% | -203.84% | -174.81% | -140.61% |
| IceCure Medical Ltd (ICCM)vs › | $3.47M | -141.90% | -194.17% | -143.89% | -113.05% |
| Evogene Ltd. (EVGN)vs › | $3.39M | N/A | 5741.84% | 2797.55% | 1847.94% |
| Eocene Ltd. (EOCN)vs › | $3.59M | N/A | N/A | N/A | N/A |
| BioRestorative Therapies, Inc. (BRTX)vs › | $3.04M | -365.43% | -2048.73% | -1082.52% | -614.77% |
| Adagio Medical Holdings, Inc. (ADGM)vs › | $3.07M | N/A | -236.13% | -104.67% | -48.54% |
| Aptevo Therapeutics Inc. (APVO)vs › | $3.98M | -437.15% | -328.44% | -188.67% | -533.64% |
| iSpecimen Inc. (ISPC)vs › | $2.64M | -657.69% | -358.53% | -220.37% | -149.08% |
| bioAffinity Technologies, Inc. (BIAF)vs › | $2.75M | -402.92% | -276.14% | -197.40% | -116.89% |
ROE
-282.1%
ROA
-206.6%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -282.13% |
| 2026-03-31 | -661.53% |
| 2025-12-31 | -483.34% |
| 2025-09-30 | -525.99% |
| 2025-06-30 | -328.17% |
| 2025-03-31 | -209.93% |
| 2024-12-31 | -143.17% |
| 2024-09-30 | -222.96% |
| 2024-06-30 | -156.22% |
| 2024-03-31 | -78.27% |
| 2023-12-31 | -108.64% |
| 2023-09-30 | -139.75% |
| 2023-06-30 | -384.52% |
| 2023-03-31 | -288.08% |
